Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (5,023)	$ (10,019)	$ (20,916)	$ (30,447)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation for property, plant and equipment			567	393
Amortization of intangible assets			965	1,009
Reduction in the carrying amount of the right-of-use assets			890	1,031
Loss on disposal of property, plant and equipment				65
Stock-based compensation expense			5,591	5,059
Acquired in-process research and development				6,555
Change in fair value of investments	(696)	3,687	2,012	205
Impairment loss of long-term investments				865
Government grant as a result of loan forgiveness				(472)
Changes in operating assets and liabilities:
Accounts receivable			(2,757)	(773)
Inventories			(3,866)	(371)
Prepaid expenses and other assets			(238)	(539)
Accounts payable			(1,073)	26
Accrued and other current liabilities and other liabilities			(1,376)	(1,770)
Deferred income			(44)	(37)
Net cash used in operating activities			(20,245)	(19,201)
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from disposal of property and equipment			138	10
Purchases of property, plant and equipment			(2,186)	(3,730)
Receipt in advance from sales of equity investment in Juventas			16,921
Cash paid to acquire in-process research and development				(6,555)
Receipt of repayment of Black Belt Convertible note				172
Net cash provided by/(used in) investing activities			13,205	(15,950)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from bank borrowings			4,001	709
Repayment of bank borrowings			(1,001)	(463)
Repurchase of common stock			(3,000)
Stock issuance costs				(2,019)
Proceeds from sale of common stock				32,500
Net cash provided by financing activities				30,727
Effect of exchange rate change on cash and cash equivalents			(2,422)	486
Net decrease in cash and cash equivalents			(9,462)	(3,938)
Cash, cash equivalents and restricted cash at beginning of period			38,704	57,064	$ 57,064
Cash, cash equivalents and restricted cash at end of period	29,242	53,126	29,242	53,126	38,704
Non-cash investing and financing activities:
Purchases of property, plant and equipment in accrued and other current liabilities			3,111	2,680
Cash and cash equivalents	26,742	53,126	26,742	53,126	38,704
Restricted cash	2,500		2,500
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	$ 29,242	$ 53,126	29,242	53,126	$ 38,704
Black Belt Tx Limited
CASH FLOWS FROM INVESTING ACTIVITIES
Cash paid to acquire convertible loan				(86)
Alesta Tx
CASH FLOWS FROM INVESTING ACTIVITIES
Cash paid to acquire convertible loan				(261)
Cleave Therapeutics, Inc
CASH FLOWS FROM INVESTING ACTIVITIES
Cash paid to acquire convertible loan				$ (5,500)
BioInvent International AB
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from sales of equity securities			1,294
Precision Autoimmune Therapeutics Co., Ltd
CASH FLOWS FROM INVESTING ACTIVITIES
Cash paid to acquire equity investment			$ (2,962)